Expert Interview
Investigating the phase III results from the ANCHOR clinical trials on depemokimab in chronic rhinosinusitis with nasal polyps.
Ticker(s): GSKInstitution: Scripps Clinic
- Allergist/Immunologist & Director, Aspirin Exacerbated Respiratory Disease Clinic,Division of Allergy, Asthma and Immunology at the Scripps Clinic.
- Currently manages 35 patients with systemic mastocytosis.
- Focus is on Aspirin exacerbated respiratory disease (AERD), mastocytosis, and mast cell activation syndromes; conducts research on aspirin exacerbated respiratory disease, a topic on which he has authored multiple publications and ongoing research protocols.
What are the current treatments available for chronic rhinosinusitis with nasal polyps, and how do you determine the progression from first-line to third-line treatment options?
Added By: slingshot_insightsHow do you manage patients who do not respond well to a biologic like Dupixent, and when do you consider switching biologics or opting for surgery?
Added By: slingshot_insightsWhat factors influence the choice of biologics, and how do you address patient concerns about injection frequency, cost, or needle anxiety?
Added By: slingshot_insightsHow does depemokimab compare to other biologics like Dupixent or omalizumab in terms of mechanism, efficacy, and the six-month dosing schedule?
Added By: slingshot_insightsWhat are the key safety concerns, side effects, and insurance coverage challenges associated with biologics, including new treatments like depemokimab?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
